Positive data from Phase III study of octreotide capsules (Mycapssa®) for the maintenance treatment of adults with acromegaly

The Phase III MPOWERED non-inferiority trial met its primary endpoint, with 91% of responders to octreotide capsules (Mycapssa®) in the 6-month run-in phase who continued on treatment maintaining IGF-1 response compared to 100% who switched back to their prior injectable therapy.

Source:

Biospace Inc.